User profiles for George Aslanidi

George Aslanidi

Hormel Institute
Verified email at umn.edu
Cited by 3589

Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats

S Shklyaev, G Aslanidi, M Tennant… - Proceedings of the …, 2003 - National Acad Sciences
Adiponectin (Acrp30) is a physiologically active polypeptide hormone secreted by adipose
tissue that shows insulin-sensitizing, antiinflammatory, and antiatherogenic properties. In …

Structure of adeno-associated virus serotype 8, a gene therapy vector

…, R McKenna, E Kohlbrenner, G Aslanidi… - Journal of …, 2007 - Am Soc Microbiol
Adeno-associated viruses (AAVs) are being developed as gene therapy vectors, and their
efficacy could be improved by a detailed understanding of their viral capsid structures. AAV …

Structural insight into the unique properties of adeno-associated virus serotype 9

…, RS Sinkovits, M Potter, BJ Byrne, G Aslanidi… - Journal of …, 2012 - Am Soc Microbiol
Adeno-associated virus serotype 9 (AAV9) has enhanced capsid-associated tropism for cardiac
muscle and the ability to cross the blood-brain barrier compared to other AAV serotypes. …

[HTML][HTML] Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors

CN Kay, RC Ryals, GV Aslanidi, SH Min, Q Ruan… - PloS one, 2013 - journals.plos.org
Development of viral vectors capable of transducing photoreceptors by less invasive methods
than subretinal injection would provide a major advancement in retinal gene therapy. We …

[HTML][HTML] Innate immune responses to AAV vectors

GL Rogers, AT Martino, GV Aslanidi… - Frontiers in …, 2011 - frontiersin.org
Gene replacement therapy by in vivo delivery of adeno-associated virus (AAV) is attractive as
a potential treatment for a variety of genetic disorders. However, while AAV has been used …

[HTML][HTML] High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines

DM Markusic, RW Herzog, GV Aslanidi, BE Hoffman… - Molecular Therapy, 2010 - cell.com
Elimination of specific surface-exposed single tyrosine (Y) residues substantially improves
hepatic gene transfer with adeno-associated virus type 2 (AAV2) vectors. Here, combinations …

[HTML][HTML] Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system

E Kohlbrenner, G Aslanidi, K Nash, S Shklyaev… - Molecular therapy, 2005 - cell.com
Scalable production of rAAV vectors remains a major obstacle to the clinical application of
this prototypical gene therapy vector. A recently developed baculovirus-based production …

[HTML][HTML] Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?

GV Aslanidi, AE Rivers, L Ortiz, L Song, C Ling… - PloS one, 2013 - journals.plos.org
The ubiquitin-proteasome pathway plays a critical role in the intracellular trafficking of AAV2
vectors, and phosphorylation of certain surface-exposed amino acid residues on the capsid …

[HTML][HTML] Microglia-specific targeting by novel capsid-modified AAV6 vectors

…, M Pardo, KL Schob, A Li, GV Aslanidi… - … Therapy Methods & …, 2016 - cell.com
Recombinant adeno-associated viruses (rAAV) have been widely used in gene therapy
applications for central nervous system diseases. Though rAAV can efficiently target neurons …

An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells

G Aslanidi, K Lamb… - Proceedings of the …, 2009 - National Acad Sciences
Production of clinical-grade gene therapy vectors for human trials remains a major hurdle in
advancing cures for a number of otherwise incurable diseases. We describe a system based …